Omeros Corporation Says Knee Drug Does Not Meet Study Goal
Business Week -- Omeros Corp. shares plunged in aftermarket trading on Thursday after the company said that its experimental knee drug did not meet goals of a late-stage clinical trial.
Omeros said it couldn't draw any conclusions about the drug's effectiveness in the study because of "confounding factors," or variables that made it impossible to tell if its drug was responsible for changes in the condition of patients. The company didn't elaborate on the nature of those factors.